Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
31JUL

Neubond seed is Japan VC's UK first

3 min read
12:32UTC

Neubond, an Imperial College London spinout building a stroke-rehab wristband, raised a £1.5m seed in June, the first UK investment by a Japanese university venture fund.

← Back to Humanoid hit $1.35bn on a customer orderJump to analysis ↓
TechnologyDeveloping
Key takeaway

Foreign capital now reaches the earliest UK stage, where domestic retail money is thinnest.

Neubond, an Imperial College London spinout, raised a £1.5m seed in June, the first UK investment by a Japanese university venture fund 1. The device is a wristband that senses a stroke patient's attempt to move a limb and delivers a small electrical pulse to the muscle, reinforcing the nerve signal and speeding the brain's relearning of movement. It reached this point on Innovate UK's ICURe (Innovation to Commercialisation of University Research) programme and Imperial's own venture support, with a European Research Council proof-of-concept award behind it.

Japanese academic capital reaching a UK seed round is new on this beat, and it lands at the earliest stage, where the retail tier has been thinning since April's tax change. Foreign money has been visible at the top of the market for months; a £1.5m round funded from a Japanese campus is the same pattern arriving one rung lower, where the cheques are smallest and the domestic supply has dropped most.

The deal also extends the spinout-engine story that ran through Midlands Mindforge's first £30m of university investments and IMU Biosciences' £40m Series A . British research keeps producing companies, and the capital backing them increasingly arrives from outside the country, now from a Japanese campus rather than a London or Silicon Valley fund.

Deep Analysis

In plain English

A stroke occurs when blood flow to part of the brain is interrupted, often killing or damaging the neurons that control movement. Many stroke survivors lose some ability to move their arms or hands. Rehabilitation works partly by encouraging the brain to form new pathways ; a process called neuroplasticity ; but it is slow, labour-intensive, and depends heavily on the patient practising movement. Neubond, a spinout from Imperial College London, has built a wristband that senses when a stroke patient is trying to move their hand and immediately sends a small electrical pulse to the relevant muscles, reinforcing the nerve signal at the moment the brain is attempting the movement. Synchronising the electrical pulse with the brain's own movement attempt accelerates the relearning process. In June 2026, Neubond raised £1.5m in a seed funding round from a Japanese university venture fund, which also marks the first time that type of investor has backed a UK company. Before this, the company was supported by Innovate UK ; the government's innovation agency ; through a programme called ICURe (Innovation to Commercialisation of University Research), which funds researchers to explore whether their work has commercial potential.

Deep Analysis
Root Causes

Neubond sits at the intersection of two structural gaps in UK innovation finance. First, the pre-Series A neurotechnology funding gap: UK medical VC concentrates at Series A and above, where clinical data supports valuation. Below that level, university spinouts depend on Innovate UK grants, ERC proof-of-concept awards, and patient institutional capital rather than commercial seed funds ; the exact funding stack Neubond has assembled.

Second, the spinout-to-company transition: UK universities have improved spinout rates significantly (DSIT's scorecard counted 655 active spinouts in 2025, ), but the commercialisation gap between an academically validated concept and a company with paying customers remains wide. ICURe specifically funds the customer-discovery and commercialisation-readiness phase that academic research grants do not cover.

What could happen next?
  • Opportunity

    Japanese university VC entering UK seed rounds for medical devices opens a new patient-capital channel for neurotechnology spinouts that require longer development timelines than commercial VCs typically accept.

  • Risk

    £1.5m is significantly below the £5–10m typically required for a pivotal clinical trial in neurotechnology; Neubond will need follow-on capital within twelve to eighteen months to reach the clinical evidence milestone that Series A investors require.

Sources:UKRI
Mentions:Imperial College London →Innovate UK →London →Beauhurst →Midlands Mindforge →Japan →IMU Biosciences →Denmark →Neubond →
First Reported In

Update #9 · Private money rebuilds Britain's seed tier

UKRI· 24 Jun 2026
Read original →
Causes and effects
Caused by
Midlands fund writes its first cheques
Midlands Mindforge's £30m of university deals showed foreign-adjacent and institutional capital reaching UK spinouts; Neubond's Japanese academic VC extends that channel.
Occurred 10 Jun 2026
Read story →
IMU raises £40m to read blood
IMU Biosciences' £40m Series A is part of the UK-research-producing-companies pattern Neubond's Japanese-funded seed continues.
Occurred 2 Jun 2026
Read story →
This Event
Neubond seed is Japan VC's UK first
A new foreign channel now reaches the earliest stage of UK funding, the very tier the domestic retail money has been draining out of.
Different Perspectives
Fubon Financial
Fubon Financial
Fubon Financial joined Humanoid's Series A on 21 July as a minority financial investor alongside Schaeffler and Bosch, who also hold the customer and manufacturer roles. A pure-play investor from Taipei is pricing a London robot maker on terms two German industrial groups effectively set.
NATO Innovation Fund
NATO Innovation Fund
The Fund joined Greenjets' £30m Series A on 21 July alongside NSSIF, betting on ducted electric propulsion's civil market to fund a technology with an obvious defence application. It is backing a company that took twenty-one years to reach this stage, on the expectation that certification-cycle timelines reward patient capital over a quick return.
Prime Movers Lab
Prime Movers Lab
Prime Movers Lab led Humanoid's Series A on 21 July as the round's only pure financial investor, sharing the cap table with two co-investors who are also the anchor customer and the factory. That leaves the fund's usual arm's-length pricing role diluted by partners with a direct commercial stake in the valuation holding up.
Bosch and Schaeffler
Bosch and Schaeffler
Schaeffler signed what Humanoid calls the industry's largest publicly announced commercial agreement, while Bosch took equity and became contract manufacturer, filling capacity a shrinking combustion supply chain freed. Neither company has disclosed a unit count or an invoice, so their public commitment stops well short of Forbes' 100,000-unit projection.
UK founders raising seed through Series A
UK founders raising seed through Series A
A London robotics founder raised $152m this week against a signed industrial customer and a reserved factory, while a Cornwall founder more typically draws a £25,000 loan from a regional fund manager. Both call it British venture funding, but one route runs through Bosch's production line and the other through diligence built for businesses too small for any VC's attention.
EQT
EQT
EQT was reported on 3 July to be in advanced talks for a further CuspAI stake on behalf of the EU's Scaleup Europe Fund, but does not appear on the round CuspAI closed. Whether Europe's own sovereign vehicle secured a position, was outbid, or withdrew is unresolved.